PA-PCI-PHARMA-SERVICES
27.7.2022 10:02:09 CEST | Business Wire | Press release
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005014/en/
“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale.”
The expansion includes two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules. A second contained manufacturing building (CMF2), capitalizing on the success of the original CMF1 which opened in 2013, will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. In addition, there is a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The primary and secondary packaging lines provide a fully integrated process, delivering end-to-end services for a global client base.
More than 1,300 medicines and vaccines in clinical trials were indicated for cancer treatment in 2021, compared to 1,100 two years prior. Oncology treatments also accounted for 25% of all medicines approved by the FDA between 2010 and 2019, signaling that oncology will remain a key focus for the industry in the upcoming years.
“The rapid evolution of oncology pipelines has coincided with the continued globalization of clinical development,” said Rebecca Coutts, Ph.D., General Manager, Tredegar, PCI Pharma Services. “This latest investment, along with the existing analytical and formulation capabilities, combines a clinical and c ommercial scale packaging facility to complement the existing clinical and increased commercial scale manufacturing capabilities, placing end-to-end services for these high-potency molecules under one roof to better serve our client’s evolving needs.”
Both facilities will contain state-of-the-art equipment, including a replica of CMF1’s large-scale granulation suite and a down-flow booth with containment screening. Duplicating the original state-of-the-art CMF1 facility will provide both greater capacity and business continuity for clients.
The Tredegar expansion is also expected to create up to 40 new jobs in the first year and add more as the facilities scale up. PCI Tredegar currently employs close to 500 people, almost doubling the number of employees since the opening of CMF1 in 2013. PCI has been operating in Tredegar UK for nearly 40 years and is one of the most significant employers in the local area. For more information on PCI’s high potent development and manufacturing capabilities, please click here .
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 13:05:00 CET | Press release
Speaking at the 2026 Singapore FinTech Festival, Ant International’s CEO Peng Yang argued that our settlement infrastructure needs to evolve beyond today’s four-party payments model to assign effectively roles and responsibilities.Ant International processed the equivalent of 1.1 trillion USD on its WhaleRTP blockchain settlement network in the last 12 months in collaboration with 23 leading global banks; expected to double in 2027.He also said that agentic economy needs to rest on a stronger multi-rail, multi-modal and multi-asset trust layer, and that good AI solutions design can power a new, more inclusive globalization project by putting the little guys on a level playing field. At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedi
NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 12:45:00 CET | Press release
Appointments add deep AI leadership and Greater China and Asia Pacific operating expertise to NIQ’s Board NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of N
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f
Pretium Expands Real Estate Debt Platform19.11.2026 12:00:00 CET | Press release
Addition of Hilltop Capital Partners Enables the Firm to Deploy Capital to the U.K. Housing Market Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a hous
SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 12:00:00 CET | Press release
SRM and Ridgemont Continue a 30+ Year Track Record of Helping Banks, Credit Unions, and Fintech Companies Unlock Growth, Innovation, and Operational Efficiency Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Busine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
